Inmune Bio Inc (INMB)
$9.58
Insights on Inmune Bio Inc
Decreasing Revenue
Revenue is down for the last 3 quarters, 46.0K → 28.0K (in $), with an average decrease of 20.7% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -8.56M → -8.40M (in $), with an average increase of 1.8% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 47.0% return, outperforming this stock by 36.5%
Performance
- $9.40$10.30$9.58
1.88%
Downside
Day's Volatility :8.76%
Upside
7.01%
- $6.50$14.74$9.58
32.15%
Downside
52 Weeks Volatility :55.9%
Upside
35.01%
Returns
| Period | Inmune Bio Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -18.81% | -0.8% | 0.0% |
6 Months | 37.25% | 5.7% | 0.0% |
1 Year | 13.37% | 3.0% | -0.7% |
3 Years | -58.29% | 14.1% | -21.8% |
Highlights
Market Capitalization | 187.3M |
Book Value | $2.08 |
Earnings Per Share (EPS) | -1.67 |
Wall Street Target Price | 19.67 |
Profit Margin | 0.0% |
Operating Margin TTM | -29925.0% |
Return On Assets TTM | -26.79% |
Return On Equity TTM | -61.09% |
Revenue TTM | 155.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | -71.1% |
Gross Profit TTM | 374.0K |
Diluted Eps TTM | -1.67 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.19 |
EPS Estimate Next Year | -1.95 |
EPS Estimate Current Quarter | -0.44 |
EPS Estimate Next Quarter | -0.58 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 105.32%
Technicals Summary
Sell
Neutral
Buy
Inmune Bio Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Inmune Bio Inc | -13.07% | 37.25% | 13.37% | -58.29% | -58.29% |
 Moderna, Inc. | -0.38% | 12.96% | -27.86% | -39.2% | 336.75% |
 Regeneron Pharmaceuticals, Inc. | -6.39% | 6.51% | 9.62% | 78.78% | 144.38% |
 Novo Nordisk A/s | -6.76% | 22.49% | 44.85% | 243.36% | 401.52% |
 Vertex Pharmaceuticals Incorporated | -3.41% | 6.25% | 21.24% | 81.12% | 121.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Inmune Bio Inc | NA | NA | NA | -2.19 | -0.61 | -0.27 | NA | 2.08 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.75 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.03 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.46 | 46.46 | 2.4 | 3.31 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.57 | 28.57 | 0.53 | 16.62 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Inmune Bio Inc | Buy | $187.3M | -58.29% | NA | 0.0% |
Moderna, Inc. | Buy | $40.3B | 336.75% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.3B | 144.38% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $564.6B | 401.52% | 46.46 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $102.5B | 121.07% | 28.57 | 36.68% |
Institutional Holdings
Vanguard Group Inc
3.01%BlackRock Inc
1.43%Rhenman Partners Asset Management AB
0.99%Geode Capital Management, LLC
0.94%Janney Montgomery Scott LLC
0.91%Deutsche Bank AG
0.61%
Corporate Announcements
Inmune Bio Inc Earnings
Inmune Bio Inc’s price-to-earnings ratio stands at None
Read More
Company Information
inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. inkmune, the company’s lead product, primes patient’s nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells’ ability to eliminate residual disease.
Organization | Inmune Bio Inc |
Employees | 11 |
CEO | Dr. Raymond Joseph Tesi M.D. |
Industry | Medical Specialties |
